Glucotrack Targets FDA IDE for CBGM Trial in 2026
RUTHERFORD, N.J., March 27, 2026 GlucoTrack announced plans to submit an Investigational Device Exemption (IDE) application to the U.S....
FDA IDE
Advertisement
Myra Vision Treats First Patient in U.S. ADAPT Glaucoma Study
CAMPBELL, CALIFORNIA | January 26, 2026 — Myra Vision, a Shifamed portfolio company, announced that the first patient has...
FDA Approves U.S. Trial for EndoArt Synthetic Corneal Implant
NES ZIONA, Israel, December 8, 2025 — EyeYon Medical Ltd. announced that the U.S. Food and Drug Administration (FDA)...
NEXTBIOMEDICAL Launches U.S. Pivotal Trial for Nexsphere-F™ in Knee OA
SEOUL, South Korea, Oct. 13, 2025 — NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), a South Korea-based innovative medical device company,...
Neuropixels Tech Enables New Brain Insights in Parkinson’s Study
AURORA, Colo., Sept. 30, 2025 — Researchers at the University of Colorado Anschutz Medical Campus announced the first FDA-authorized...
Advertisement
